Request a FREE Sample of our FcRn Binding Kit!Request a FREE Sample of our Fc gamma RI / CD64 Binding Kit !
Happy Holiday! Limited Keychain here with your next orderHappy Holiday! Limited Keychain here with your next order
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
5e5 of anti-IL-3 R alpha CAR-293 cells were stained with 100 μL of 1:25 dilution (4 μL stock solution in 100 μL FACS buffer) of APC-Labeled Human IL-3 R alpha Protein, His Tag (Cat. No. ILA-HA2H8) and negative control protein respectively. APC signal was used to evaluate the binding activity (QC tested).
5e5 of anti-IL-3 R alpha CAR-293 cells were stained with 100 μL of 1:25 dilution (4 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human IL-3 R alpha, His Tag (Cat. No. ILA-HP2H8) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).
Anti-IL-3 R alpha Antibody, Human IgG1 immobilized on CM5 Chip can bind Human IL-3 R alpha, Fc Tag (Cat. No. ILA-H5252) with an affinity constant of 50.3 nM as determined in a SPR assay (Biacore T200) (QC tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Tagraxofusp | SL-401; DTIL-3; DT388 IL3 | Approved | Texas A&M University Development Foundation | Elzonris | United States | Blastic Plasmacytoid Dendritic Cell Neoplasm | Stemline Therapeutics Inc | 2018-12-21 | Leukemia; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Multiple Myeloma; Blastic Plasmacytoid Dendritic Cell Neoplasm; Primary Myelofibrosis; Leukemia, Myeloid, Acute; Lymphoma | Details |
Tagraxofusp | SL-401; DTIL-3; DT388 IL3 | Approved | Texas A&M University Development Foundation | Elzonris | United States | Blastic Plasmacytoid Dendritic Cell Neoplasm | Stemline Therapeutics Inc | 2018-12-21 | Leukemia; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Multiple Myeloma; Blastic Plasmacytoid Dendritic Cell Neoplasm; Primary Myelofibrosis; Leukemia, Myeloid, Acute; Lymphoma | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
CD123/CLL1 CAR-T Cell Therapy (Fujian Medical University) | Phase 3 Clinical | Fujian Medical University | Leukemia, Myeloid, Acute | Details | |
Flotetuzumab | S-80880; MGD-006; RES-234 | Phase 2 Clinical | Macrogenics Inc | Leukemia, Myelogenous, Chronic; Hematologic Neoplasms; Leukemia; Leukemia, Hairy Cell; Mastocytosis, Systemic; Hodgkin Disease; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Neoplasms, Plasma Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Leukemia, Myeloid, Acute; Leukemia, Biphenotypic, Acute | Details |
Talacotuzumab | CSL-362; JNJ-473; CSL-362-AML; JNJ-56022473; IL-13 MAb-CSL | Phase 2 Clinical | Csl Ltd | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
Vibecotamab | XmAb-14045 | Phase 2 Clinical | Xencor Inc | Leukemia, Myeloid; Myelodysplastic Syndromes; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details |
Pivekimab sunirine | IMGN-632 | Phase 2 Clinical | Immunogen Inc | Bone Marrow Neoplasms; Leukemia; Myeloproliferative Disorders; Myelodysplastic Syndromes; Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, Myeloid, Acute | Details |
CD123 CAR-T cell therapy(Chongqing Precision Biotechnology) | Phase 2 Clinical | Chongqing Precision Biotechnology Co Ltd | Leukemia; Leukemia, Myeloid; Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, Myeloid, Acute | Details | |
Anti-CD123 CAR T-cell therapy (Southwest Hospital) | Phase 2 Clinical | Southwest Hospital Chongqing | Leukemia, Myeloid | Details | |
AZD-9829 | AZD-9829; AZD9829 | Phase 2 Clinical | Astrazeneca Plc | Hematologic Diseases; Hematologic Neoplasms; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
Anti Tim-3/CD123 CAR-T Cell Therapy(Xuzhou Medical University) | Phase 2 Clinical | Xuzhou Medical University (Xzmu), The Affiliated Hospital Of Xuzhou Medical University | Leukemia, Myeloid, Acute | Details | |
MP0533 | MP0533 | Phase 2 Clinical | Molecular Partners Ag | Leukemia, Myeloid, Acute | Details |
APVO-436 | APVO-436; APVO436 | Phase 2 Clinical | Aptevo | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
SAR-443579 | SAR-443579; SAR443579; SAR579; IPH6101; IPH-6101 | Phase 2 Clinical | Sanofi | Hematologic Diseases; Myelodysplastic Syndromes; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Leukemia, Myeloid, Acute | Details |
Anti-CD123 CAR T-cell therapy (University of Pennsylvania/Novartis) | JEZ-567 | Phase 1 Clinical | Novartis Pharma Ag, University Of Pennsylvania | Leukemia, Myeloid, Acute | Details |
UCART-123 | UCART-123 | Phase 1 Clinical | Cellectis Sa | Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, Myeloid, Acute | Details |
JNJ-63709178 | JNJ-9178; CNTO-9958; JNJ-63709178 | Phase 1 Clinical | Johnson & Johnson Innovative Medicine, Genmab A/S | Leukemia, Myeloid, Acute | Details |
Anti-CD123 CAR T cell therapy (Shanghai GeneChem) | Phase 1 Clinical | Shanghai Genechem Co Ltd | Leukemia, Myeloid, Acute | Details | |
IM-23 (Beijing Immunochina Medical Science and Technology) | IM-23; IM-23 CAR-T | Phase 1 Clinical | Beijing Immunochina Medical Science & Technology Co Ltd | Leukemia, Myeloid, Acute | Details |
Anti-CD123 CAR T-cell therapy (Nanjing Legend Biotech) | Phase 1 Clinical | Leukemia, Myeloid, Acute | Details | ||
MB-102 (Mustang Bio) | MB-102 | Phase 1 Clinical | Mustang Bio Inc, City Of Hope National Medical Center | Neoplasm, Residual; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Leukemia, Biphenotypic, Acute | Details |
UniCAR-T-CD-123 | UniCAR-T-CD123; AVC-101 | Phase 1 Clinical | AvenCell Therapeutics Inc, AvenCell Europe GmbH | Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, Myeloid, Acute | Details |
Anti-CD123 CAR-T cell therapy (Wuhan Union Hospital) | Phase 1 Clinical | Wuhan BioRaid Biotechnology Co Ltd, Wuhan Union Hospital | Leukemia, Myeloid, Acute | Details | |
CD123 CAR-T cells (Hebei Senlang Biotechnology) | Phase 1 Clinical | Hebei Senlang Biological Technology Co Ltd | Leukemia, Myeloid, Acute | Details | |
ACLX-002 | ACLX-002 | Phase 1 Clinical | Arcellx Inc | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
MGD-024 | MGD-024 | Phase 1 Clinical | Macrogenics Inc | Leukemia, Myelogenous, Chronic; Leukemia, Hairy Cell; Hodgkin Disease; Myelodysplastic Syndromes; Neoplasms; Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, B-Cell; Leukemia, Myeloid, Acute | Details |
AFM-28 | AFM-28 | Phase 1 Clinical | Affimed | Leukemia, Promyelocytic, Acute; Neoplasms; Leukemia, Myeloid, Acute | Details |
VIP943 | BAY-943; VIP-943 | Phase 1 Clinical | Bayer AG | Myelodysplastic Syndromes; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details |
CD123 CAR-NK cell therapy(Beijing JD Biotech) | JD123; JD-123 | Phase 1 Clinical | Peking University People'S Hospital, Beijing JD Biotech Co Ltd | Leukemia, Myeloid, Acute | Details |
Universal CAR-T Cells therapy(Shenzhen Geno-Immune Medical Institute) | Phase 1 Clinical | Shenzhen Geno-Immune Medical Institute | Leukemia, Myeloid, Acute | Details | |
AVC-201 | AVC-201; Allo-RevCAR01-T-CD123 | Phase 1 Clinical | AvenCell Europe GmbH | Leukemia, Myeloid, Acute | Details |
CD123-CAR T cells(St Jude Children's Research Hospital) | Phase 1 Clinical | St Jude Children's Research Hospital | Myelodysplastic Syndromes; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Burkitt Lymphoma | Details | |
Allogenic CD123-CAR-NK Cells therapy(JD Biotech) | JD023 | Phase 1 Clinical | Beijing JD Biotech Co Ltd, Chinese Academy Of Military Medical Sciences | Leukemia, Myeloid, Acute | Details |
BYON-4413 | BYON-4413 | Phase 1 Clinical | Byondis Bv | Hematologic Neoplasms; Leukemia, Myeloid, Acute | Details |
GR-1901 | GR1901; GR-1901 | Phase 1 Clinical | Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd, Genrix (Shanghai) Biopharmaceutical Co Ltd | Leukemia, Myeloid, Acute | Details |
SQZ-622(Novartis Pharma) | SQZ-622 | Phase 1 Clinical | Novartis Pharma Ag | Leukemia, Myeloid, Acute | Details |
UniCAR02-T | UniCAR02-T | Phase 1 Clinical | Cellex Patient Treatment Gmbh | Kidney Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
IL3 CAR T-cell therapy (Yake Biotechnology) | Phase 1 Clinical | Zhejiang University | Leukemia, Myeloid, Acute | Details | |
CD123/CLL1 CAR-T Cell Therapy (Fujian Medical University) | Phase 3 Clinical | Fujian Medical University | Leukemia, Myeloid, Acute | Details | |
Flotetuzumab | S-80880; MGD-006; RES-234 | Phase 2 Clinical | Macrogenics Inc | Leukemia, Myelogenous, Chronic; Hematologic Neoplasms; Leukemia; Leukemia, Hairy Cell; Mastocytosis, Systemic; Hodgkin Disease; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Neoplasms, Plasma Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Leukemia, Myeloid, Acute; Leukemia, Biphenotypic, Acute | Details |
Talacotuzumab | CSL-362; JNJ-473; CSL-362-AML; JNJ-56022473; IL-13 MAb-CSL | Phase 2 Clinical | Csl Ltd | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
Vibecotamab | XmAb-14045 | Phase 2 Clinical | Xencor Inc | Leukemia, Myeloid; Myelodysplastic Syndromes; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details |
Pivekimab sunirine | IMGN-632 | Phase 2 Clinical | Immunogen Inc | Bone Marrow Neoplasms; Leukemia; Myeloproliferative Disorders; Myelodysplastic Syndromes; Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, Myeloid, Acute | Details |
CD123 CAR-T cell therapy(Chongqing Precision Biotechnology) | Phase 2 Clinical | Chongqing Precision Biotechnology Co Ltd | Leukemia; Leukemia, Myeloid; Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, Myeloid, Acute | Details | |
Anti-CD123 CAR T-cell therapy (Southwest Hospital) | Phase 2 Clinical | Southwest Hospital Chongqing | Leukemia, Myeloid | Details | |
AZD-9829 | AZD-9829; AZD9829 | Phase 2 Clinical | Astrazeneca Plc | Hematologic Diseases; Hematologic Neoplasms; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
Anti Tim-3/CD123 CAR-T Cell Therapy(Xuzhou Medical University) | Phase 2 Clinical | Xuzhou Medical University (Xzmu), The Affiliated Hospital Of Xuzhou Medical University | Leukemia, Myeloid, Acute | Details | |
MP0533 | MP0533 | Phase 2 Clinical | Molecular Partners Ag | Leukemia, Myeloid, Acute | Details |
APVO-436 | APVO-436; APVO436 | Phase 2 Clinical | Aptevo | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
SAR-443579 | SAR-443579; SAR443579; SAR579; IPH6101; IPH-6101 | Phase 2 Clinical | Sanofi | Hematologic Diseases; Myelodysplastic Syndromes; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Leukemia, Myeloid, Acute | Details |
Anti-CD123 CAR T-cell therapy (University of Pennsylvania/Novartis) | JEZ-567 | Phase 1 Clinical | Novartis Pharma Ag, University Of Pennsylvania | Leukemia, Myeloid, Acute | Details |
UCART-123 | UCART-123 | Phase 1 Clinical | Cellectis Sa | Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, Myeloid, Acute | Details |
JNJ-63709178 | JNJ-9178; CNTO-9958; JNJ-63709178 | Phase 1 Clinical | Johnson & Johnson Innovative Medicine, Genmab A/S | Leukemia, Myeloid, Acute | Details |
Anti-CD123 CAR T cell therapy (Shanghai GeneChem) | Phase 1 Clinical | Shanghai Genechem Co Ltd | Leukemia, Myeloid, Acute | Details | |
IM-23 (Beijing Immunochina Medical Science and Technology) | IM-23; IM-23 CAR-T | Phase 1 Clinical | Beijing Immunochina Medical Science & Technology Co Ltd | Leukemia, Myeloid, Acute | Details |
Anti-CD123 CAR T-cell therapy (Nanjing Legend Biotech) | Phase 1 Clinical | Leukemia, Myeloid, Acute | Details | ||
MB-102 (Mustang Bio) | MB-102 | Phase 1 Clinical | Mustang Bio Inc, City Of Hope National Medical Center | Neoplasm, Residual; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Leukemia, Biphenotypic, Acute | Details |
UniCAR-T-CD-123 | UniCAR-T-CD123; AVC-101 | Phase 1 Clinical | AvenCell Therapeutics Inc, AvenCell Europe GmbH | Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, Myeloid, Acute | Details |
Anti-CD123 CAR-T cell therapy (Wuhan Union Hospital) | Phase 1 Clinical | Wuhan BioRaid Biotechnology Co Ltd, Wuhan Union Hospital | Leukemia, Myeloid, Acute | Details | |
CD123 CAR-T cells (Hebei Senlang Biotechnology) | Phase 1 Clinical | Hebei Senlang Biological Technology Co Ltd | Leukemia, Myeloid, Acute | Details | |
ACLX-002 | ACLX-002 | Phase 1 Clinical | Arcellx Inc | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
MGD-024 | MGD-024 | Phase 1 Clinical | Macrogenics Inc | Leukemia, Myelogenous, Chronic; Leukemia, Hairy Cell; Hodgkin Disease; Myelodysplastic Syndromes; Neoplasms; Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, B-Cell; Leukemia, Myeloid, Acute | Details |
AFM-28 | AFM-28 | Phase 1 Clinical | Affimed | Leukemia, Promyelocytic, Acute; Neoplasms; Leukemia, Myeloid, Acute | Details |
VIP943 | BAY-943; VIP-943 | Phase 1 Clinical | Bayer AG | Myelodysplastic Syndromes; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details |
CD123 CAR-NK cell therapy(Beijing JD Biotech) | JD123; JD-123 | Phase 1 Clinical | Peking University People'S Hospital, Beijing JD Biotech Co Ltd | Leukemia, Myeloid, Acute | Details |
Universal CAR-T Cells therapy(Shenzhen Geno-Immune Medical Institute) | Phase 1 Clinical | Shenzhen Geno-Immune Medical Institute | Leukemia, Myeloid, Acute | Details | |
AVC-201 | AVC-201; Allo-RevCAR01-T-CD123 | Phase 1 Clinical | AvenCell Europe GmbH | Leukemia, Myeloid, Acute | Details |
CD123-CAR T cells(St Jude Children's Research Hospital) | Phase 1 Clinical | St Jude Children's Research Hospital | Myelodysplastic Syndromes; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Burkitt Lymphoma | Details | |
Allogenic CD123-CAR-NK Cells therapy(JD Biotech) | JD023 | Phase 1 Clinical | Beijing JD Biotech Co Ltd, Chinese Academy Of Military Medical Sciences | Leukemia, Myeloid, Acute | Details |
BYON-4413 | BYON-4413 | Phase 1 Clinical | Byondis Bv | Hematologic Neoplasms; Leukemia, Myeloid, Acute | Details |
GR-1901 | GR1901; GR-1901 | Phase 1 Clinical | Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd, Genrix (Shanghai) Biopharmaceutical Co Ltd | Leukemia, Myeloid, Acute | Details |
SQZ-622(Novartis Pharma) | SQZ-622 | Phase 1 Clinical | Novartis Pharma Ag | Leukemia, Myeloid, Acute | Details |
UniCAR02-T | UniCAR02-T | Phase 1 Clinical | Cellex Patient Treatment Gmbh | Kidney Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
IL3 CAR T-cell therapy (Yake Biotechnology) | Phase 1 Clinical | Zhejiang University | Leukemia, Myeloid, Acute | Details |
This web search service is supported by Google Inc.